Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients
Autor: | Syed Shahzad Hasan, Muhammad Abdul Hadi, Chia Siang Kow, Sallianne Kavanagh, Amie Bain, Hamid A. Merchant |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Blood Glucose
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Comorbidity Glycemic Control Incretins Patient Care Planning 03 medical and health sciences Deprescriptions 0302 clinical medicine Adrenal Cortex Hormones Diabetes mellitus Internal medicine Humans Hypoglycemic Agents Insulin Medicine In patient Pharmacology (medical) Sodium-Glucose Transporter 2 Inhibitors Monitoring Physiologic Pharmacology Dipeptidyl-Peptidase IV Inhibitors SARS-CoV-2 business.industry COVID-19 General Medicine medicine.disease Metformin Hospitalization Diabetes Mellitus Type 1 Diabetes Mellitus Type 2 Hyperglycemia 030220 oncology & carcinogenesis Thiazolidinediones Disease Susceptibility business 030217 neurology & neurosurgery |
Zdroj: | Expert Opinion on Pharmacotherapy |
ISSN: | 1744-7666 1465-6566 |
DOI: | 10.1080/14656566.2020.1837114 |
Popis: | Diabetes mellitus is one of the most prevalent comorbidities identified in patients with coronavirus disease 2019 (COVID-19). This article aims to discuss the pharmacotherapeutic considerations for the management of diabetes in hospitalized patients with COVID-19.We discussed various aspects of pharmacotherapeutic management in hospitalized patients with COVID-19: (i) susceptibility and severity of COVID-19 among individuals with diabetes, (ii) glycemic goals for hospitalized patients with COVID-19 and concurrent diabetes, (iii) pharmacological treatment considerations for hospitalized patients with COVID-19 and concurrent diabetes.The glycemic goals in patients with COVID-19 and concurrent type 1 (T1DM) or type 2 diabetes (T2DM) are to avoid disruption of stable metabolic state, maintain optimal glycemic control, and prevent adverse glycemic events. Patients with T1DM require insulin therapy at all times to prevent ketosis. The management strategies for patients with T2DM include temporary discontinuation of certain oral antidiabetic agents and consideration for insulin therapy. Patients with T2DM who are relatively stable and able to eat regularly may continue with oral antidiabetic agents if glycemic control is satisfactory. Hyperglycemia may develop in patients with systemic corticosteroid treatment and should be managed upon accordingly. |
Databáze: | OpenAIRE |
Externí odkaz: |